Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Escalation Study of DMT in Humans
NCT04711915Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- Mar 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DMT in major depressive disorder (MDD) (2 arms), sponsored by Yale University. Primary endpoints: Change in Blood Pressure at 120 months, Change in Heart Rate at 120 months and 4 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
DMT
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04711915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711915.